ZimVie (NASDAQ:ZIMV) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of ZimVie (NASDAQ:ZIMV – Get Rating) in a research note issued to investors on Friday, The Fly reports. The firm issued a neutral rating on the stock.

A number of other research analysts have also issued reports on ZIMV. Credit Suisse Group started coverage on ZimVie in a report on Tuesday, March 1st. They issued an underperform rating and a $34.00 target price for the company. Guggenheim began coverage on ZimVie in a research note on Friday, March 18th. They issued a neutral rating on the stock.

NASDAQ:ZIMV opened at $18.08 on Friday. The company has a fifty day moving average of $22.91. ZimVie has a 12-month low of $17.53 and a 12-month high of $50.40. The company has a quick ratio of 1.41, a current ratio of 2.50 and a debt-to-equity ratio of 0.72.

In other ZimVie news, insider Vafa Jamali purchased 10,000 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were bought at an average cost of $20.04 per share, for a total transaction of $200,400.00. Following the completion of the purchase, the insider now directly owns 100,030 shares in the company, valued at $2,004,601.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

About ZimVie (Get Rating)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.

Featured Articles

• Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
• Vuzix Stock Stays Optimistic
• Palo Alto Networks: Pioneering AI in Cybersecurity
• Dividend Stocks and Your Roth IRA
• The Analysts Upgrade… Retail Stocks? 
• The Q2 Earnings Season Could Be A Bloodbath 

Want More Great Investing Ideas?